VOICED : Merck pide en EEUU autorización para una píldora contra el covid-19

Merck has requested emergency approval in the U.S. for Molnupiravir, a COVID-19 antiviral pill. Clinical trials showed it reduced hospitalization and death rates compared to a placebo. The drug works by reducing the virus's ability to reproduce, effective against all variants. Experts caution it is not a cure and should complement vaccines. Merck aims to produce 10 million treatments by the end of 2021.

What did Merck announce regarding their COVID-19 treatment?

• They are merging with another pharmaceutical company.

• They have developed a vaccine.

• They are seeking emergency approval for a COVID-19 pill.

• They have stopped all COVID-19 research.

What was the hospitalization or death rate for those who received Molnupiravir in the trial?

• 14.1%

• 10.2%

• 7.3%

• 20.5%

How does Molnupiravir help in treating COVID-19?

• By increasing antibody production.

• By reducing the virus's ability to replicate.

• By boosting the immune system.

• By replacing damaged cells.

What is the expected production target for Molnupiravir by the end of 2021?

• 15 million treatments

• 10 million treatments

• 20 million treatments

• 5 million treatments

What do experts say about the use of Molnupiravir in relation to vaccines?

• It should replace vaccines.

• It is a miracle cure.

• It is only effective against one variant.

• It should complement vaccines, not replace them.